| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 737 | 2.078 | 2.580 | 5.233 | 7.727 | 7.961 | 8.758 | 14.247 | 11.208 |
| Total Income - EUR | - | 737 | 2.078 | 2.580 | 5.233 | 7.727 | 7.961 | 8.758 | 35.037 | 11.208 |
| Total Expenses - EUR | - | 667 | 1.348 | 620 | 193 | 194 | 398 | 314 | 21.526 | 1.100 |
| Gross Profit/Loss - EUR | - | 70 | 730 | 1.961 | 5.040 | 7.533 | 7.563 | 8.444 | 13.512 | 10.107 |
| Net Profit/Loss - EUR | - | 48 | 668 | 1.883 | 4.883 | 7.350 | 7.369 | 8.236 | 11.916 | 8.682 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Neurodermamed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 69 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | 699 | 2.520 | 4.822 | 9.660 | 16.913 | 24.093 | 12.225 | 39.848 | 53.079 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.790 | 25.150 |
| Receivables | - | 0 | 0 | 0 | 0 | 0 | 0 | 6.550 | 320 | 213 |
| Cash | - | 699 | 2.520 | 4.822 | 9.660 | 16.913 | 24.093 | 5.674 | 18.737 | 27.716 |
| Shareholders Funds | - | 92 | 759 | 2.628 | 7.461 | 14.669 | 21.713 | 8.285 | 14.578 | 23.179 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 676 | 1.761 | 2.194 | 2.199 | 2.244 | 2.379 | 3.940 | 25.270 | 29.900 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neurodermamed Srl